Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CEO INTERVIEW: JULIA GREENSTEIN - IMMERGE BIOTHERAPEUTICS INC.


(PAJ200) JULIA GREENSTEIN - IMMERGE im·merge  
intr.v. im·merged, im·merg·ing, im·merg·es
To submerge or disappear in or as if in a liquid.



[Latin immergere; see immerse.
 BIOTHERAPEUTICS INC. Describes the company's business and its background; prospects for the industry, with positive and negative trends; competitive threats; strategic opportunities for the firm including its marketing plans and acquisition potential; management strength and organization; and the financial prospects of the firm looking forward. Sector: Biotechnology. Published date 5/8/02. Complete text approximately 3000 words. Document # PAJ200.

CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  INTERVIEWS, The Wall Street Transcript, 67 Wall Street, NY 10005. Voice (212) 952 7433. Fax: (212) 668-9842. E-mail: transcript@twst.com.

***
COPYRIGHT 2002 Wall Street Transcript Corporation
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Comment:CEO INTERVIEW: JULIA GREENSTEIN - IMMERGE BIOTHERAPEUTICS INC.(Brief Article)
Publication:Wall Street Transcript Digest
Article Type:Brief Article
Geographic Code:1USA
Date:Jun 10, 2002
Words:85
Previous Article:CEO INTERVIEW: MICHAEL BISHOP - INFIGEN INC.
Next Article:ANALYST INTERVIEW: REPORTING ON BIOTECHNOLOGY: JUSTIN GILLIS - THE WASHINGTON POST.
Topics:



Related Articles
BioTransplant, Novartis say newly named Immerge BioTherapeutics began operations January 2.
Infigen, Immerge BioTherapeutics collaborate to clone knock-out pigs for xenotransplant research.
Infigen terminates agreement with Pharming Holding.
Arthritis found in Dolly the sheep.
Cloned pigs with rejection gene eliminated raises hopes for breakthrough in xenotransplantation.
Cloning's ups and downs. (Biomedicine).
Advanced Cell announces license of its cloning.
Cloned pigs raise transplant hopes.
Advanced Cell Technology revails in cloning patent dispute.
CEO INTERVIEW: DANIEL C. MONTANO - CARDIOVASCULAR BIOTHERAPEUTICS, INC. (CVBT).

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles